ICH Topic Q 2 A Validation of Analytical Methods: Definitions and Terminology

Similar documents
ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)

GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS.

Validation and Calibration. Definitions and Terminology

ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

Guidance for Industry

ANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS

OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT

Applying Statistics Recommended by Regulatory Documents

Assay Development and Method Validation Essentials

Analytical Methods: A Statistical Perspective on the ICH Q2A and Q2B Guidelines for Validation of Analytical Methods

ICH Topic Q 5 E Comparability of Biotechnological/Biological Products

Working with ICH Quality Guidelines - the Canadian Perspective

Analytical Test Method Validation Report Template

Design of Experiments for Analytical Method Development and Validation

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

Implementing New USP Chapters for Analytical Method Validation

Validating Methods using Waters Empower TM 2 Method. Validation. Manager

ICH Topic Q 1 E Evaluation of Stability Data. Step 5 NOTE FOR GUIDANCE ON EVALUATION OF STABILITY DATA (CPMP/ICH/420/02)

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT

QbD Approach to Assay Development and Method Validation

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

Guideline on Process Validation

FOOD FOR THOUGHT Topical Insights from our Subject Matter Experts UNDERSTANDING WHAT IS NEEDED TO PRODUCE QUALITY DATA

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

Questions and answers on post approval change management protocols

IMPURITIES IN NEW DRUG PRODUCTS

European Medicines Agency

CMD(v)/GUI/014. GUIDANCE for The Processing of Generic Applications Through MRP / DCP

Definition of Minimum Performance Requirements for Analytical Methods of GMO Testing European Network of GMO Laboratories (ENGL)

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

To avoid potential inspection

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

Guideline on stability testing for applications for variations to a marketing authorisation

Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice

Workshop B Control Strategy

Guide to Method Validation for Quantitative Analysis in Chemical Testing Laboratories

11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07

ICH Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products. Step 5

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

A Stability Program for the Distribution of Drug Products

A commitment to quality and continuous improvement

American Association for Laboratory Accreditation

Develop a Quantitative Analytical Method for low (» 1 ppm) levels of Sulfate

Draft agreed by Pharmacokinetics Working Party January Adoption by CHMP for release for consultation 17 February 2011

Guidance for Industry

Intelligent use of Relative Response Factors in Gas Chromatography-Flame Ionisation Detection

ASSURING THE QUALITY OF TEST RESULTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

ICH Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Step 5

Evaluating Current Practices in Shelf Life Estimation

Draft Agreed by Pharmacokinetics Working Party January End of consultation (deadline for comments) 31 May 2011

USING CLSI GUIDELINES TO PERFORM METHOD EVALUATION STUDIES IN YOUR LABORATORY

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS

Performance and advantages of qnmr measurements

Analytical Procedures and Methods Validation for Drugs and Biologics

Development and Validation of In Vitro Diagnostic Tests. YC Lee, Ph.D. CEO

Assay Qualification Template for Host Cell Protein ELISA

Guidance for Industry

ERDOSTEINE - MONOGRAPH.

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

4.2 Bias, Standards and Standardization

Method Validation. Introduction. Página Web 1 de 16

METHOD 9075 TEST METHOD FOR TOTAL CHLORINE IN NEW AND USED PETROLEUM PRODUCTS BY X-RAY FLUORESCENCE SPECTROMETRY (XRF)

Content Sheet 7-1: Overview of Quality Control for Quantitative Tests

Ecology Quality Assurance Glossary

RESOLUTION-RDC Nr- 48, OF OCTOBER 6, 2009

Methods verification. Transfer of validated methods into laboratories working routine. Dr. Manuela Schulze 1

Revision of The Dissolution Procedure: Development and Validation 1092

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.

Carolina s Solution Preparation Manual

Mass Spectrometry Signal Calibration for Protein Quantitation

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., FRUCTUS

How to Verify Performance Specifications

Annex 2 Stability testing of active pharmaceutical ingredients and finished pharmaceutical products

Understanding Analytical Chemistry (Weighing, Mixing, Measuring and Evaluating)

Manufacture of Certified Reference Materials AuRM3 for London Bullion Market Association

General and statistical principles for certification of RM ISO Guide 35 and Guide 34

CHMP/BWP (COMMITTEE ABBREVIATION) GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS

Questions and answers on post approval change management protocols

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)

STABILITY TESTING: PHOTOSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS

ICH guideline Q8, Q9 and Q10 - questions and answers volume 4

Procedure for Equipment Calibration and Maintenance

Technical Report. Automatic Identification and Semi-quantitative Analysis of Psychotropic Drugs in Serum Using GC/MS Forensic Toxicological Database

Simultaneous Qualitative and Quantitative Data Acquisition for Research of Diabetes Drugs

Expectations for Data to Support Clinical Trial Drugs

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants

Procedure for Writing Technical Procedures

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS

The Basic Principles of Sieve Analysis

Annex 7 Guidelines on pre-approval inspections

ISO How to Meet. Requirements for Method Verification. Prepared by:

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER

OLIVÉR BÁNHIDI 1. Introduction

Transcription:

The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/381/95 ICH Topic Q 2 A Validation of Analytical Methods: Definitions and Terminology Step 5 NOTE FOR GUIDANCE ON VALIDATION OF ANALYTICAL METHODS: DEFINITIONS AND TERMINOLOGY (CPMP/ICH/381/95) APPROVAL BY CPMP November 1994 DATE FOR COMING INTO OPERATION (STUDIES COMMENCING AFTER) 1 June 1995 ICH - Technical Coordination - R. Bass 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel: (+44-171) 418 84 11 Fax: (+44-171) 418 85 51 E_Mail: mail@emea.eudra.org http://www.eudra.org/emea.html

VALIDATION OF ANALYTICAL METHODS: DEFINITIONS AND TERMINOLOGY ICH Harmonised Tripartite Guideline [EMEA Status as of November 1994] 1. INTRODUCTION This document presents a discussion of the characteristics for consideration during the validation of the analytical procedures included as part of registration applications submitted within the EC, Japan and USA. This document does not necessarily seek to cover the testing that may be required for registration in, or export to, other areas of the world. Furthermore, this text presentation serves as a collection of terms, and their definitions, and is not intended to provide direction on how to accomplish validation. These terms and definitions are meant to bridge the differences that often exist between various compendia and regulators of the EC, Japan and USA. The objective of validation of an analytical procedure is to demonstrate that it is suitable for its intended purpose. A tabular summation of the characteristics applicable to identification, control of impurities and assay procedures is included. Other analytical procedures may be considered in future additions to this document. 2. TYPES OF ANALYTICAL PROCEDURES TO BE VALIDATED The discussion of the validation of analytical procedures is directed to the four most common types of analytical procedures: Identification tests. Quantitative tests for impurities' content. Limit tests for the control of impurities. Quantitative tests of the active moiety in samples of drug substance or drug product or other selected component(s) in the drug product. Although there are many other analytical procedures, such as dissolution testing for drug products or particle size determination for drug substance, these have not been addressed in the initial text on validation of analytical procedures. Validation of these additional analytical procedures is equally important to those listed herein and may be addressed in subsequent documents. A brief description of the types of tests considered in this document is provided below. Identification tests are intended to ensure the identity of an analyte in a sample. This is normally achieved by comparison of a property of the sample (e.g., spectrum, chromatographic behavior, chemical reactivity, etc) to that of a reference standard. CPMP/ICH/381/95 1/5

Testing for impurities can be either a quantitative test or a limit test for the impurity in a sample. Either test is intended to accurately reflect the purity characteristics of the sample. Different validation characteristics are required for a quantitative test than for a limit test. Assay procedures are intended to measure the analyte present in a given sample. In the context of this document, the assay represents a quantitative measurement of the major component(s) in the drug substance. For the drug product, similar validation characteristics also apply when assaying for the active or other selected component(s). The same validation characteristics may also apply to assays associated with other analytical procedures (e.g., dissolution). The objective of the analytical procedure should be clearly understood since this will govern the validation characteristics which need to be evaluated. Typical validation characteristics which should be considered are listed below: Accuracy Precision Repeatability Intermediate Precision Specificity Detection Limit Quantitation Limit Linearity Range Each of these validation characteristics is defined in the attached Glossary. The table lists those validation characteristics regarded as the most important for the validation of different types of analytical procedures. This list should be considered typical for the analytical procedures cited but occasional exceptions should be dealt with on a case-by-case basis. It should be noted that robustness is not listed in the table but should be considered at an appropriate stage in the development of the analytical procedure. Furthermore revalidation may be necessary in the following circumstances: changes in the synthesis of the drug substance; changes in the composition of the finished product; changes in the analytical procedure; The degree of revalidation required depends on the nature of the changes. Certain other changes may require validation as well. CPMP/ICH/381/95 2/5

TABLE Type of analytical procedure IDENTIFICATION TESTING FOR IMPURITIES ASSAY - dissolution (measurement only) - content/potency characteristics quantitat.limit Accuracy - + - + Precision Repeatability Interm.Precision - - + - + (1) - Specificity (2) + + + + Detection Limit - - (3) + - Quantitation Limit - + - - Linearity - + - + Range - + - + + + (1) - signifies that this characteristic is not normally evaluated + signifies that this characteristic is normally evaluated (1) in cases where reproducibility (see glossary) has been performed, intermediate precision is not needed (2) lack of specificity of one analytical procedure could be compensated by other supporting analytical procedure(s) (3) may be needed in some cases CPMP/ICH/381/95 3/5

GLOSSARY 1. Analytical Procedure The analytical procedure refers to the way of performing the analysis. It should describe in detail the steps necessary to perform each analytical test. This may include but is not limited to: the sample, the reference standard and the reagents preparations, use of the apparatus, generation of the calibration curve, use of the formulae for the calculation, etc. 2. Specificity Specificity is the ability to assess unequivocally the analyte in the presence of components which may be expected to be present. Typically these might include impurities, degradants, matrix, etc. Lack of specificity of an individual analytical procedure may be compensated by other supporting analytical procedure(s). This definition has the following implications: Identification: Purity Tests: to ensure the identity of an analyte. to ensure that all the analytical procedures performed allow an accurate statement of the content of impurities of an analyte, i.e. related substances test, heavy metals, residual solvents content, etc. Assay (content or potency): 3. Accuracy to provide an exact result which allows an accurate statement on the content or potency of the analyte in a sample. The accuracy of an analytical procedure expresses the closeness of agreement between the value which is accepted either as a conventional true value or an accepted reference value and the value found. This is sometimes termed trueness. 4. Precision The precision of an analytical procedure expresses the closeness of agreement (degree of scatter) between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions. Precision may be considered at three levels: repeatability, intermediate precision and reproducibility. Precision should be investigated using homogeneous, authentic samples. However, if it is not possible to obtain a homogeneous sample it may be investigated using artificially prepared samples or a sample solution. The precision of an analytical procedure is usually expressed as the variance, standard deviation or coefficient of variation of a series of measurements. CPMP/ICH/381/95 4/5

4.1. Repeatability Repeatability expresses the precision under the same operating conditions over a short interval of time. Repeatability is also termed intra-assay precision. 4.2. Intermediate precision Intermediate precision expresses within-laboratories variations: different days, different analysts, different equipment, etc. 4.3. Reproducibility Reproducibility expresses the precision between laboratories (collaborative studies, usually applied to standardization of methodology). 5. Detection Limit The detection limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value. 6. Quantitation Limit The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and/or degradation products. 7. Linearity The linearity of an analytical procedure is its ability (within a given range) to obtain test results which are directly proportional to the concentration (amount) of analyte in the sample. 8. Range The range of an analytical procedure is the interval between the upper and lower concentration (amounts) of analyte in the sample (including these concentrations) for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy and linearity. 9. Robustness The robustness of an analytical procedure is a measure of its capacity to remain unaffected by small, but deliberate variations in method parameters and provides an indication of its reliability during normal usage. CPMP/ICH/381/95 5/5